EP1278508A1 - Plant extract of the species i vitis vinifera /i as no-synthase inhibitor and uses - Google Patents
Plant extract of the species i vitis vinifera /i as no-synthase inhibitor and usesInfo
- Publication number
- EP1278508A1 EP1278508A1 EP01929749A EP01929749A EP1278508A1 EP 1278508 A1 EP1278508 A1 EP 1278508A1 EP 01929749 A EP01929749 A EP 01929749A EP 01929749 A EP01929749 A EP 01929749A EP 1278508 A1 EP1278508 A1 EP 1278508A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- composition
- use according
- intended
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Definitions
- Vitis vinifera plant extract as a NO synthase inhibitor and uses
- the subject of the present invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition , the extract or composition being intended to inhibit NO-synthase.
- NO-synthase covers a family of enzymes which ensure the enzymatic catalysis of L-arginine into citrulline, during which catalysis is produced a gaseous mediator with multiple functions, nitrogen monoxide or NO.
- NO-synthases exist in three forms, two constitutive forms, nomenclature grouping together neuronal NO-synthase (or NOS 1) and endothelial NO-synthase (or NOS 3), and the inducible form (or NOS 2) (Medicine / Sciences , 1992, 8, pp. 843-845).
- NO-synthase covers all of the isoforms of the enzyme.
- NO-synthase inhibitors is understood to mean any product which, in the end, results, notwithstanding the isoform of NO-synthase, in the reduction of the concentration of NO.
- Nitric oxide has, by its structure, an additional electron making it extremely chemically reactive. It is well known that such compounds are harmful and we seek to limit their production as much as possible. Thus, in the case of nitric oxide, the NO-synthase inhibitors have been widely studied.
- NO is a multifunctional signal molecule active in a wide variety of body systems and tissues.
- cardiovascular system regulatory of blood pressure with vasodilator effect, inhibitor of platelet aggregation with anticoagulant effect
- nerve system mesoid aggregation with anticoagulant effect
- immunological system modulation of immune defenses, inflammation, involvement in autoimmune pathologies.
- NO plays a predominant role in the skin. NO can be synthesized by all varieties of cells constituting the skin and as such it intervenes in multiple and complex regulatory processes such as the regulation of cell differentiation and / or proliferation, vasodilation, melanogenesis , response to environmental variations (homeostasis).
- NO is involved in apoptotic processes and in intrinsic and / or extrinsic aging of the skin. It is involved in the skin's immunological and inflammatory processes. It is indeed commonly accepted that NO plays a role in contact hypersensitivity reactions, in allergic skin manifestations, in the skin's immune response. Similarly, in addition to its direct proinflammatory role, it is the mediator between neuropeptides such as substance P and or the peptide associated with the calcitonin gene (calcitonin gene related peptide or CGRP) in cutaneous neurogenic inflammatory processes, hence its involvement. in so-called sensitive skin phenomena. The implication of.
- NO in vasodilation causes it to be associated with skin erythema, particularly erythema induced by ultraviolet radiation, localized or diffuse erythematous rashes on the skin such as those caused by drugs, toxins and / or viral or bacterial infections , with rosacea.
- NO is recognized as an intermediary in melanogenesis induced by type B ultraviolet radiation (UVB). It is also one of the factors involved in hypermelanosis-like disorders. NO also seems to be involved in the control of sweating as well as in that of lipolysis (inhibitory effect) or even in hair loss. Finally, NO is known to have an influence on the barrier function of the skin and therefore on its hydration (inhibitory effect). We therefore understand the interest that exists in having inhibitors of NO-synthases. In this regard, numerous inhibitors have already been proposed in the prior art.
- NMMA N G -monomethyl-L-arginine
- NAME N G -nitro-L-arginine
- NNA N G -nitro-L-arginine
- NAA N G - amino-L-arginine
- ADMA diphenyleneiodonium chloride
- 2- (4-carboxyphenyl) -4,4,5 5-tetramethylimidazoline-1 -oxy-3-oxide
- the object of the present invention is to provide a new inhibitor of NO-synthase which is moreover a natural inhibitor of NO-synthase.
- an extract of at least one plant of the species Vitis vinifera has the property of being an inhibitor of NO-synthase, in particular of inducible NO-synthase (NOS 2) which makes it a good candidate for uses in applications where it turns out to be advantageous to use a NO-synthase inhibitor, particularly in cosmetics.
- NOS 2 inducible NO-synthase
- Plant extracts of the Vitis vinifera species are known in the prior art as promoting vasodilation or also as being able to be used in compositions intended for skin and / or hair care.
- an extract of at least one plant of the species Vitis vinifera has the property of being an inhibitor of NO synthase, particularly of inducible NO synthase (OUR 2).
- a primary object of the invention is therefore the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to inhibit NO-synthase, particularly inducible NO-synthase (NOS 2).
- physiologically acceptable medium is understood a medium compatible with the skin, mucous membranes, nails, hair.
- a second object of the invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended for application in all fields in which inhibition of NO synthases, particularly of inducible NO synthase (NOS 2), proves to be necessary, particularly in the skin area and / or capillary.
- NOS 2 inducible NO synthase
- the plant extract of the Vitis vinifera species or the composition containing it can be used to slow down or even inhibit cell differentiation and / or proliferation, and / or vasodilation, and / or melanogenesis, and / or response to environmental variations (homeostasis).
- the third object of the invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to slow down or even inhibit cell differentiation and / or proliferation, in particular to regulate the growth of the epidermis and / or to treat hyperproliferative disorders such as for example psoriasis.
- a fourth object of the invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to inhibit the degradation and / or destruction of cells and to inhibit apoptotic processes, particularly skin cells, very particularly keratinocytes and / or to treat intrinsic aging and / or extrinsic cells, especially skin cells.
- a fifth object of the invention is the use of an effective amount of at least one extract of at least one plant of the Vitis vinifera species, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to inhibit or even suppress the immunological and / or inflammatory processes linked to the synthesis of NO, such as for example contact hypersensitivity reactions and / or allergic manifestations and / or the immune response, particularly in the skin.
- the extract or the composition are intended to reduce or even inhibit skin inflammation, very particularly the neurogenic inflammatory skin processes, and therefore to treat so-called sensitive skin.
- the sixth object of the invention is the use of an effective amount of at least one extract of at least one plant of the Vitis vinifera species, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to treat rosacea and / or skin erythemas, particularly erythemas induced by ultraviolet radiation and or localized or diffuse erythematous rashes of the skin such as those caused by drugs toxins and / or viral or bacterial infections.
- the seventh subject of the invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to inhibit melanogenesis induced by ultraviolet radiation of type A and or B and / or to treat disorders of hypermelanosis type.
- the eighth object of the invention is the use of an effective amount of at least one extract of at least one plant of the Vitis vinifera species, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to control sweating and / or to stimulate lipolysis and / or to inhibit hair loss and / or to reinforce the barrier function of the skin and / or to stimulate the hydration of the skin.
- the composition comprising the extract can be a cosmetic or dermatological composition.
- the composition is a cosmetic composition.
- the extract or the composition comprising it is applied to the skin topically.
- the plant of the species Vitis vinifera is one of the 28 plant species belonging to the genus Vitis which itself belongs to the family of Ampelidae.
- the extract can be prepared from at least any one of the numerous varieties associated with each of the plant species belonging to the genus Vitis. It is therefore understood that in the text the term Vitis vinifera must be understood as designating any one of the numerous plant varieties associated with each of the plant species belonging to the genus Vitis and particularly as designating the species Vitis vinifera.
- the plant extract of the species Vitis vinifera can be any extract prepared from any plant material obtained from at least one plant of the genus Vitis.
- Vitis vinifera used according to the invention can be obtained from plant material obtained from whole plants or from parts of plants such as leaves, stems, flowers, petals, seeds, roots. or even dedifferentiated cells.
- dedifferentiated plant cells any plant cell having none of the characteristics of a particular specialization and capable of living by itself and not in dependence on other cells.
- an extract prepared from green leaves is used.
- the extract of at least one plant of the genus Vitis can be any extract prepared from any plant material derived from at least one plant of the genus Vitis cultivated in vivo or derived from culture in vitro.
- in vivo culture means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
- in vitro culture means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant.
- the selection pressure imposed by the physicochemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material available throughout the year. unlike plants grown in vivo.
- a plant originating from culture in vivo is used.
- Mention may in particular be made of aqueous extracts, alcoholic extracts or those using an organic solvent.
- aqueous solvent means any solvent consisting wholly or partly of water. Mention may thus be made of water itself, hydroalcoholic solvents in any proportion or even solvents consisting of water and a compound such as propylene glycol in any proportion.
- the plant material is ground in a cold aqueous solution
- the particles in suspension are removed from the aqueous solution obtained from the first step
- the aqueous solution obtained from the second step is obtained from the second step.
- This aqueous solution corresponds to the extract.
- the first step can advantageously be replaced by a simple freezing operation of the plant tissues (for example at -20 ° C.), followed by an aqueous extraction repeating the second and third steps described above.
- the extract obtained can be lyophilized by any conventional lyophilization method.
- a powder is thus obtained which can be used directly or else mix in an appropriate solvent before use.
- an extract sold by the company Euromed under the name Leucocyanidins from extra grapes is used.
- the amount of plant extract of the species Vitis vinifera used in the composition is of course a function of the desired effect and can therefore vary to a large extent.
- the extract can be used in an amount representing from 10 "4 % to 20% of the total weight of the composition and preferably in an amount representing from 5.10 " 3 % to 10% of the total weight of the composition.
- the extract of at least one plant of the Vitis vinifera species can be combined with other NO-synthase inhibitors such as, for example, lipochroman-6, or other plant extracts such as example an extract of Ginkgo biloba, an extract of Olea europaea or an extract of green tea or cocoa.
- NO-synthase inhibitors such as, for example, lipochroman-6, or other plant extracts such as example an extract of Ginkgo biloba, an extract of Olea europaea or an extract of green tea or cocoa.
- the ninth subject of the invention is a cosmetic treatment process with a view to treating disorders linked to the synthesis of NO, characterized in that it is used by application on the skin, on the hair, and / or on the mucous membranes , a cosmetic composition comprising at least one extract of at least one plant of the Vitis vinifera species in a physiologically acceptable medium.
- the cosmetic treatment method of the invention aims to improve the appearance of the individual affected by the disorders due to the synthesis of NO.
- the cosmetic treatment process of the invention can be implemented in particular by applying the cosmetic compositions as defined above, according to the usual technique for using these compositions.
- the cosmetic compositions as defined above, according to the usual technique for using these compositions.
- it is possible to carry out applications of creams, gels, serums, lotions, cleansing milks or anti-sun compositions on the skin or on dry hair, applications of a hair lotion on wet hair, shampoos, or even toothpaste applications on the gums.
- the extract it can be ingested, injected or applied to the skin (on any cutaneous zone of the body), the hair, the nails or the mucous membranes ( buccal, jugale, gingival, genital, conjunctiva).
- the composition according to the invention can be in all the dosage forms normally used.
- the composition may take the form in particular of an aqueous or oily solution or of a dispersion of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a phase fatty in an aqueous phase (O / W) or vice versa (W / O), or of suspensions or emulsions of soft consistency of the aqueous or anhydrous cream or gel type, or of microcapsules or microparticles, or of vesicular dispersions of the ionic type and / or non-ionic.
- These compositions are prepared according to the usual methods.
- They can also be used for the hair in the form of aqueous, alcoholic or hydroalcoholic solutions, or in the form of creams, gels, emulsions, foams or also in the form of aerosol compositions also comprising a propellant under pressure.
- the composition may be in the form of an aqueous, oily lotion or in the form of a serum.
- the eyes it can be in the form of drops and for ingestion, it can be in the form of capsules, granules of syrups or tablets.
- compositions according to the invention are those conventionally used in the fields considered.
- compositions constitute in particular cleansing, protective, treatment or care creams for the face, for the hands, for the feet, for large anatomical folds or for the body (for example day creams, night creams, make-up remover creams, foundation creams, sunscreen creams), fluid foundations, make-up removal milks, body protection or care milks, anti-sun milks, lotions, gels or foams for care skin, such as cleansing lotions, sunscreen lotions, artificial tanning lotions, bath compositions, deodorant compositions comprising a bactericidal agent, aftershave gels or lotions, depilatory creams, compositions against insect bites, pain relieving compositions, compositions for treating certain skin diseases such as eczema, rosacea, psoriasis, lichens, severe pruritus.
- compositions according to the invention may also consist of solid preparations constituting soaps or cleaning bars.
- compositions can also be packaged in the form of an aerosol composition also comprising a propellant under pressure.
- the composition according to the invention may also be a composition for hair care, and in particular a shampoo, a styling lotion, a treating lotion, a styling cream or gel, a composition of dyes (in particular oxidation dyes) in the form of coloring shampoos, restructuring hair lotions, a perm composition (in particular a composition for the first time of a perm), a fall prevention lotion or gel, an antiparasitic shampoo, etc.
- a composition for hair care and in particular a shampoo, a styling lotion, a treating lotion, a styling cream or gel, a composition of dyes (in particular oxidation dyes) in the form of coloring shampoos, restructuring hair lotions, a perm composition (in particular a composition for the first time of a perm), a fall prevention lotion or gel, an antiparasitic shampoo, etc.
- the composition can also be for oral use, for example a toothpaste.
- the composition may contain adjuvants and additives customary for compositions for oral use and in particular surfactants, thickening agents, humectants, polishing agents such as silica, various active ingredients such as fluorides, in particular particularly sodium fluoride, and optionally sweetening agents such as sodium saccharinate.
- the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition.
- the oils, waxes, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic field.
- the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
- the emulsion may, in addition, contain lipid vesicles.
- the fatty phase may represent more than 90% of the total weight of the composition.
- the cosmetic composition may also contain adjuvants customary in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and coloring matters.
- adjuvants customary in the cosmetic field such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and coloring matters.
- the amounts of these various adjuvants are those conventionally used in the cosmetic field, and for example from 0.01% to 10% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid spherules.
- emulsifiers which can be used in the invention, there may be mentioned for example glycerol stearate, polysorbate 60 and the mixture of PEG-6 / PEG-32 / Glycol Stearate sold under the name Tefose R 63 by the company Gattefosse.
- solvents which can be used in the invention mention may be made of lower alcohols, in particular ethanol and isopropanol, propylene glycol.
- hydrophilic gelling agents which can be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, ethylcellulose, polyethylene.
- carboxyvinyl polymers carboxyvinyl polymers
- acrylic copolymers such as acrylate / alkylacrylate copolymers
- polyacrylamides polysaccharides
- polysaccharides such as hydroxypropylcellulose
- natural gums and clays and, as lipophilic gelling agents
- modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica,
- composition may contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, plant extracts and hydroxy acids.
- hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, plant extracts and hydroxy acids.
- retinol and its derivatives
- tocopherol vitamin E
- essential fatty acids ceramides
- essential oils ceramides
- the composition can combine at least one extract of at least one plant of the Vitis vinifera species with other active agents intended in particular for the prevention and / or treatment of skin conditions.
- active agents there may be mentioned by way of example:
- agents modulating differentiation and / or proliferation and / or skin pigmentation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, kojic acid or hydroquinone;
- - antibacterials such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline class
- - antifungals in particular compounds belonging to the class of imidazoles such as Peconazole, ketoconazole or miconazole or their salts, polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine , or octopirox;
- non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid, acetaminophen or glycyrrhetinic acid;
- - anesthetic agents such as lidocaine hydrochloride and its derivatives
- - antipruritic agents such as thenaldine, trimeprazine or cyproheptadine;
- - keratolytic agents such as alpha- and beta-hydroxycarboxylic or beta-ketocarboxylic acids, their salts, amides or esters and more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, acid citric and generally fruit acids, and n-octanoyl-5-salicylic acid;
- - anti-free radical agents such as alpha-tocopherol or its esters, superoxide dismutases, certain metal chelating agents or ascorbic acid and its esters;
- anti-dandruff agents such as octopirox or zinc pyrithione
- anti-acne drugs such as retinoic acid or benzoyl peroxide
- - plant or microbial extracts
- compositions illustrate the invention without limiting it in any way.
- proportions indicated are percentages by weight.
- A positive control (induction of the enzyme): mixtures of interferon- ⁇ (1 OOOU / ml) and Interleukin 1- ⁇ (100 U / ml);
- B negative control (maximum inhibition): N G -monomethyl-L-arginine (form L) at 200 ⁇ M;
- C inhibition specificity control: N G -monomethyl-L-arginine (form D) at
- the quantity of stable NO reaction products is measured using the “nitric colorimetric assay” kit sold by the company Boehringer under the reference 1756.28.
- the extracts have an inhibitory effect on inducible NO synthase.
- Composition 1 Lotion
- Composition 2 Gel for care
- Composition 3 Care cream (oil in water emulsion)
- Composition 4 Shampoo
- Composition 5 Care cream (oil / water emulsion)
- Composition 6 Pain relieving gel
- Composition 7 Sun erythema care cream (oil-in-water emulsion)
- Composition 8 Gel for the treatment of acne
- Composition 9 Lotion for eliminating scars due to acne
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention concerns the use of an efficient amount of at least an extract of a plant of the species <i>Vitis vinifera</i> in a physiologically acceptable medium, in a composition or for preparing a composition, the extract or the composition being designed to inhibit NO-synthase.
Description
Extrait de végétal de l'espèce Vitis vinifera comme inhibiteur de NO-synthase et utilisations Vitis vinifera plant extract as a NO synthase inhibitor and uses
La présente invention a pour objet l'utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physioiogiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à inhiber la NO-synthase.The subject of the present invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition , the extract or composition being intended to inhibit NO-synthase.
Le terme NO-synthase recouvre une famille d'enzymes qui assurent la catalyse enzymatique de la L-arginine en citrulline, catalyse au cours de laquelle est produit un médiateur gazeux aux multiples fonctions, le monoxyde d'azote ou NO.The term NO-synthase covers a family of enzymes which ensure the enzymatic catalysis of L-arginine into citrulline, during which catalysis is produced a gaseous mediator with multiple functions, nitrogen monoxide or NO.
Les NO-synthases existent sous trois formes, deux formes constitutives, nomenclature regroupant la NO-synthase neuronale (ou NOS 1) et la NO-synthase endothéliale (ou NOS 3), et la forme inductible (ou NOS 2) (Médecine/Sciences, 1992, 8, pp. 843-845).NO-synthases exist in three forms, two constitutive forms, nomenclature grouping together neuronal NO-synthase (or NOS 1) and endothelial NO-synthase (or NOS 3), and the inducible form (or NOS 2) (Medicine / Sciences , 1992, 8, pp. 843-845).
On comprend par ailleurs dans le texte que sans indication contraire le terme NO-synthase recouvre l'ensemble des isoformes de l'enzyme.It is also understood in the text that without the contrary indication the term NO-synthase covers all of the isoforms of the enzyme.
Ainsi, selon l'invention on entend par inhibiteurs de NO-synthase, tout produit qui in fineconduit, nonobstant l'isoforme de NO-synthase, à la diminution de la concentration de NO. On peut citer à titre d'exemple les produits qui diminuent la quantité de NO-synthase active, qui bloquent l'activité enzymatique de la NO- synthase ou son induction ou qui inhibent l'activité du NO produit.Thus, according to the invention, the term NO-synthase inhibitors is understood to mean any product which, in the end, results, notwithstanding the isoform of NO-synthase, in the reduction of the concentration of NO. By way of example, mention may be made of products which reduce the amount of active NO-synthase, which block the enzymatic activity of NO-synthase or its induction or which inhibit the activity of NO produced.
Le monoxyde d'azote possède de par sa structure un électron supplémentaire le rendant extrêmement réactif chimiquement. Il est notoire que de tels composés sont nocifs et l'on cherche à limiter au mieux leur production. C'est ainsi que dans le cas du monoxyde d'azote les inhibiteurs de NO-synthase ont été largement étudiés.Nitric oxide has, by its structure, an additional electron making it extremely chemically reactive. It is well known that such compounds are harmful and we seek to limit their production as much as possible. Thus, in the case of nitric oxide, the NO-synthase inhibitors have been widely studied.
Le NO est une molécule signal multifonctionnelle active dans une grande variété de systèmes et de tissus du corps. Outre ses effets dommageables pour les cellules liés à son hyperréactivité due à sa structure comprenant un électron supplémentaire, elle est reconnue entre autre comme intervenant particulièrement dans le système cardiovasculaire (régulateur de la pression sanguine avec effet vasodilatateur, inhibiteur de l'agrégation plaquettaire avec
effet anticoagulant), dans le système nerveux (mémoire, modulation de la libération des neurotransmetteurs), dans le système immunologique (modulation des défenses immunitaires, inflammation, implication dans les pathologies auto- immunes).NO is a multifunctional signal molecule active in a wide variety of body systems and tissues. In addition to its damaging effects on cells linked to its hyperreactivity due to its structure comprising an additional electron, it is recognized, among other things, as intervening particularly in the cardiovascular system (regulator of blood pressure with vasodilator effect, inhibitor of platelet aggregation with anticoagulant effect), in the nervous system (memory, modulation of neurotransmitter release), in the immunological system (modulation of immune defenses, inflammation, involvement in autoimmune pathologies).
Il est maintenant bien admis que le NO joue un rôle prépondérant dans la peau. Le NO peut être synthétisé par toutes les variétés de cellules constituant la peau et à ce titre il intervient dans de multiples et complexes processus de régulation tels que la régulation de la différenciation et/ou de la prolifération cellulaire, de la vasodilatation, de la mélanogenèse, de la réponse aux variations environnementales (homéostasie).It is now well recognized that NO plays a predominant role in the skin. NO can be synthesized by all varieties of cells constituting the skin and as such it intervenes in multiple and complex regulatory processes such as the regulation of cell differentiation and / or proliferation, vasodilation, melanogenesis , response to environmental variations (homeostasis).
Son implication dans la différenciation et la prolifération cellulaire (effet , stimulateur), particulièrement des keratinocytes, l'associe aussi bien à la croissance de l'épiderme et à la cicatrisation qu'aux désordres hyperprolifératifs (psoriasis).Its involvement in cell differentiation and proliferation (effect, stimulator), particularly of keratinocytes, associates it as well with the growth of the epidermis and scarring as with hyperproliferative disorders (psoriasis).
Du fait de son hyperréactivité électronique pouvant entraîner une dégradation voire une destruction des cellules, le NO est impliqué dans les processus apoptotiques et dans le vieillissement intrinsèque et/ou extrinsèque de la peau. Il intervient dans les processus immunologiques et inflammatoires cutanés. Il est en effet communément admis que le NO joue un rôle dans les réactions d'hypersensibilité de contact, dans les manifestations allergiques cutanées, dans la réponse immunitaire de la peau. De même, outre son rôle proinflammatoire direct, il est le médiateur entre les neuropeptides comme la substance P et ou le peptide associé au gène de la calcitonine (calcitonin gène related peptide ou CGRP) dans les processus inflammatoires neurogéniques cutanés, d'où son implication dans les phénomènes de peau dite sensible. L'implication du. NO dans la vasodilatation fait qu'il est associé aux érythèmes cutanés, particulièrement les érythèmes induits par les rayonnements ultra-violets, aux éruptions érythémateuses localisées ou diffuses de la peau comme celles causées par les drogues les toxines et/ou les infections virales ou bactériennes, à la rosacée.Due to its electronic hyperreactivity which can lead to degradation or even destruction of cells, NO is involved in apoptotic processes and in intrinsic and / or extrinsic aging of the skin. It is involved in the skin's immunological and inflammatory processes. It is indeed commonly accepted that NO plays a role in contact hypersensitivity reactions, in allergic skin manifestations, in the skin's immune response. Similarly, in addition to its direct proinflammatory role, it is the mediator between neuropeptides such as substance P and or the peptide associated with the calcitonin gene (calcitonin gene related peptide or CGRP) in cutaneous neurogenic inflammatory processes, hence its involvement. in so-called sensitive skin phenomena. The implication of. NO in vasodilation causes it to be associated with skin erythema, particularly erythema induced by ultraviolet radiation, localized or diffuse erythematous rashes on the skin such as those caused by drugs, toxins and / or viral or bacterial infections , with rosacea.
Le NO est reconnu comme intermédiaire dans la mélanogenèse induite par les rayonnements ultra-violets de type B (UVB). Il serait aussi un des facteurs intervenant dans les désordres de type hypermélanose. Le NO semble également impliqué dans le contrôle de la sudation ainsi que dans celui de la lipolyse (effet inhibiteur) ou encore dans la chute des cheveux. Enfin, le NO est connu pour avoir une influence sur la fonction barrière de la peau et donc sur l'hydratation de celle-ci (effet inhibiteur).
On comprend donc l'intérêt qui existe à disposer d'inhibiteurs des NO-synthases. A cet égard de nombreux inhibiteurs ont déjà été proposés dans l'art antérieur. On peut citer plus particulièrement la NG-monométhyl-L-arginine (NMMA), l'ester méthylé de la NG-nitro-L-arginine (NAME), la NG-nitro-L-arginine (NNA), la NG- amino-L-arginine (NAA), la NG.NG-diméthyl-arginine (la diméthylarginine asymétrique, dénommée ADMA), le chlorure de diphénylèneiodonium, le 2-(4-carboxyphényl)-4,4,5,5-tetraméthylimidazoline-1 -oxy-3-oxyde, laNO is recognized as an intermediary in melanogenesis induced by type B ultraviolet radiation (UVB). It is also one of the factors involved in hypermelanosis-like disorders. NO also seems to be involved in the control of sweating as well as in that of lipolysis (inhibitory effect) or even in hair loss. Finally, NO is known to have an influence on the barrier function of the skin and therefore on its hydration (inhibitory effect). We therefore understand the interest that exists in having inhibitors of NO-synthases. In this regard, numerous inhibitors have already been proposed in the prior art. Mention may more particularly be made of N G -monomethyl-L-arginine (NMMA), the methyl ester of N G -nitro-L-arginine (NAME), N G -nitro-L-arginine (NNA), N G - amino-L-arginine (NAA), N G .N G -dimethyl-arginine (asymmetric dimethylarginine, called ADMA), diphenyleneiodonium chloride, 2- (4-carboxyphenyl) -4,4,5 , 5-tetramethylimidazoline-1 -oxy-3-oxide, la
7-nitroindazole, la N(5)-(1-iminoéthyl)-L-omithine, l'aminoguanidine, la canavanine et l'ebselen.7-nitroindazole, N (5) - (1-iminoethyl) -L-omithine, aminoguanidine, canavanine and ebselen.
Sans mettre en doute l'efficacité de ces produits, on note qu'il s'agit de composés chimiques qui peuvent induire des désagréments chez l'utilisateur voire des effets secondaires néfastes, qui de manière générale préfère utiliser des produits naturels.Without questioning the effectiveness of these products, we note that these are chemical compounds which can induce inconvenience in the user or even harmful side effects, who generally prefer to use natural products.
Le but de la présente invention est de fournir un nouvel inhibiteur de NO-synthase qui plus est un inhibiteur naturel de NO-synthase.The object of the present invention is to provide a new inhibitor of NO-synthase which is moreover a natural inhibitor of NO-synthase.
De manière surprenante et inattendue, la demanderesse a démontré qu'un extrait d'au moins un végétal de l'espèce Vitis vinifera présente la propriété d'être un inhibiteur de NO-synthase, particulièrement de la NO-synthase inductible (NOS 2) ce qui en fait un bon candidat pour des utilisations dans des applications où il s'avère intéressant d'utiliser un inhibiteur de NO-synthase, particulièrement en cosmétique.Surprisingly and unexpectedly, the applicant has demonstrated that an extract of at least one plant of the species Vitis vinifera has the property of being an inhibitor of NO-synthase, in particular of inducible NO-synthase (NOS 2) which makes it a good candidate for uses in applications where it turns out to be advantageous to use a NO-synthase inhibitor, particularly in cosmetics.
Les extraits de végétal de l'espèce Vitis vinifera sont connus dans l'art antérieur comme favorisant la vasodilatation ou encore comme pouvant être utilisés dans de compositions destinées aux soins de la peau et/ou des cheveux.Plant extracts of the Vitis vinifera species are known in the prior art as promoting vasodilation or also as being able to be used in compositions intended for skin and / or hair care.
Mais à la connaissance de la demanderesse il n'a jamais été décrit qu'un extrait d'au moins un végétal de l'espèce Vitis vinifera présente la propriété d'être un inhibiteur de NO-synthase, particulièrement de la NO-synthase inductible (NOS 2).However, to the applicant's knowledge, it has never been described that an extract of at least one plant of the species Vitis vinifera has the property of being an inhibitor of NO synthase, particularly of inducible NO synthase (OUR 2).
L'invention a donc pour objet premier l'utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physiologiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à inhiber la NO-synthase, particulièrement de la NO-synthase inductible (NOS 2).
Par milieu physiologiquement acceptable, on comprend un milieu compatible avec la peau, les muqueuses, les ongles, les cheveux.A primary object of the invention is therefore the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to inhibit NO-synthase, particularly inducible NO-synthase (NOS 2). By physiologically acceptable medium is understood a medium compatible with the skin, mucous membranes, nails, hair.
L'invention a pour second objet l'utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physiologiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à une application dans tous les domaines dans lesquels une inhibition des NO-synthases, particulièrement de la NO-synthase inductible (NOS 2), s'avère nécessaire, particulièrement dans le domaine cutané et/ou capillaire.A second object of the invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended for application in all fields in which inhibition of NO synthases, particularly of inducible NO synthase (NOS 2), proves to be necessary, particularly in the skin area and / or capillary.
Ainsi, l'extrait de végétal de l'espèce Vitis vinifera ou la composition le contenant peuvent être utilisés pour ralentir voire inhiber la différenciation et/ou la prolifération cellulaire, et/ou la vasodilatation, et/ou la mélanogenèse, et/ou la réponse aux variations environnementales (homéostasie).Thus, the plant extract of the Vitis vinifera species or the composition containing it can be used to slow down or even inhibit cell differentiation and / or proliferation, and / or vasodilation, and / or melanogenesis, and / or response to environmental variations (homeostasis).
Ainsi, l'invention a pour troisième objet l'utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physiologiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à ralentir voire inhiber la différenciation et/ou la prolifération cellulaire, particulièrement à réguler la croissance de l'épiderme et/ou à traiter les désordres hyperprolifératifs comme par exemple le psoriasis.Thus, the third object of the invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to slow down or even inhibit cell differentiation and / or proliferation, in particular to regulate the growth of the epidermis and / or to treat hyperproliferative disorders such as for example psoriasis.
L'invention a pour quatrième objet l'utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physiologiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à inhiber la dégradation et/ou la destruction des cellules et à inhiber les processus apoptotiques, particulièrement des cellules de la peau, très particulièrement des keratinocytes et/ou à traiter le vieillissement intrinsèque et/ou extrinsèque des cellules, particulièrement des cellules de la peau.A fourth object of the invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to inhibit the degradation and / or destruction of cells and to inhibit apoptotic processes, particularly skin cells, very particularly keratinocytes and / or to treat intrinsic aging and / or extrinsic cells, especially skin cells.
L'invention a pour cinquième objet l'utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physiologiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à inhiber voire
supprimer les processus immunologiques et/ou inflammatoires liés à la synthèse de NO, comme par exemple les réactions d'hypersensibilité de contact et/ou les manifestations allergiques et/ou la réponse immunitaire, particulièrement au niveau de la peau.A fifth object of the invention is the use of an effective amount of at least one extract of at least one plant of the Vitis vinifera species, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to inhibit or even suppress the immunological and / or inflammatory processes linked to the synthesis of NO, such as for example contact hypersensitivity reactions and / or allergic manifestations and / or the immune response, particularly in the skin.
Particulièrement, l'extrait ou la composition sont destinés à diminuer voir inhiber l'inflammation cutanée, très particulièrement les processus inflammatoires neurogéniques cutanés, et donc à traiter les peaux dites sensibles.In particular, the extract or the composition are intended to reduce or even inhibit skin inflammation, very particularly the neurogenic inflammatory skin processes, and therefore to treat so-called sensitive skin.
L'invention a pour sixième objet l'utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physiologiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à traiter la rosacée et/ou les érythèmes cutanés, particulièrement les érythèmes induits par les rayonnements ultra-violets et ou les éruptions érythémateuses localisées ou diffuses de la peau comme celles causées par les drogues les toxines et/ou les infections virales ou bactériennes.The sixth object of the invention is the use of an effective amount of at least one extract of at least one plant of the Vitis vinifera species, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to treat rosacea and / or skin erythemas, particularly erythemas induced by ultraviolet radiation and or localized or diffuse erythematous rashes of the skin such as those caused by drugs toxins and / or viral or bacterial infections.
L'invention a pour septième objet l'utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physiologiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à inhiber la mélanogenèse induite par les rayonnements ultra-violets de type A et ou B et/ou à traiter les désordres de type hypermélanose.The seventh subject of the invention is the use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to inhibit melanogenesis induced by ultraviolet radiation of type A and or B and / or to treat disorders of hypermelanosis type.
L'invention a pour huitième objet l'utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physiologiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à contrôler la sudation et/ou à stimuler la lipolyse et/ou a inhiber la chute des cheveux et/ou à renforcer la fonction barrière de la peau et/ou à stimuler l'hydratation de la peau.The eighth object of the invention is the use of an effective amount of at least one extract of at least one plant of the Vitis vinifera species, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to control sweating and / or to stimulate lipolysis and / or to inhibit hair loss and / or to reinforce the barrier function of the skin and / or to stimulate the hydration of the skin.
Selon l'invention, la composition comprenant l'extrait peut être une composition cosmétique ou dermatologique. Préférentiellement selon l'invention, la composition est une composition cosmétique.According to the invention, the composition comprising the extract can be a cosmetic or dermatological composition. Preferably according to the invention, the composition is a cosmetic composition.
Préférentiellement selon l'invention, l'extrait ou la composition le comprenant est appliqué sur la peau de manière topique.
Le végétal de l'espèce Vitis vinifera est l'une des 28 espèces végétales appartenant au genre Vitis qui lui même appartient à la famille des Ampélidées.Preferably according to the invention, the extract or the composition comprising it is applied to the skin topically. The plant of the species Vitis vinifera is one of the 28 plant species belonging to the genus Vitis which itself belongs to the family of Ampelidae.
Bien entendu, l'extrait peut être préparé à partir d'au moins l'une quelconque des nombreuses variétés associées à chacune des espèces végétales appartenant au genre Vitis. On comprend donc que dans le texte le terme Vitis vinifera doit s'entendre comme désignant l'une quelconque des nombreuses variétés végétales associées à chacune des espèces végétales appartenant au genre Vitis et particulièrement comme désignant l'espèce Vitis vinifera.Of course, the extract can be prepared from at least any one of the numerous varieties associated with each of the plant species belonging to the genus Vitis. It is therefore understood that in the text the term Vitis vinifera must be understood as designating any one of the numerous plant varieties associated with each of the plant species belonging to the genus Vitis and particularly as designating the species Vitis vinifera.
L'extrait de végétal de l'espèce Vitis vinifera peut être tout extrait préparé à partir de tout matériel végétal issu d'au moins un végétal du genre Vitis.The plant extract of the species Vitis vinifera can be any extract prepared from any plant material obtained from at least one plant of the genus Vitis.
Ainsi, de végétal de l'espèce Vitis vinifera utilisé selon l'invention peut être obtenu à partir de matériel végétal issu de plante entière ou de parties de plante comme les feuilles, les tiges, les fleurs, les pétales, les graines, les racines ou encore des cellules dédifférenciées.Thus, from the plant of the species Vitis vinifera used according to the invention can be obtained from plant material obtained from whole plants or from parts of plants such as leaves, stems, flowers, petals, seeds, roots. or even dedifferentiated cells.
Par cellules végétales dédifférenciées, on entend toute cellule végétale ne présentant aucun des caractères d'une spécialisation particulière et capable de vivre par elle-même et non en dépendance avec d'autres cellules.By dedifferentiated plant cells is meant any plant cell having none of the characteristics of a particular specialization and capable of living by itself and not in dependence on other cells.
Préférentiellement selon l'invention on utilise un extrait préparé à partir de feuilles vertes.Preferably according to the invention, an extract prepared from green leaves is used.
L'extrait d'au moins un végétal du genre Vitis peut être tout extrait préparé à partir de tout matériel végétal issu d'au moins un végétal du genre Vitis cultivé in vivo ou issu de culture in vitro.The extract of at least one plant of the genus Vitis can be any extract prepared from any plant material derived from at least one plant of the genus Vitis cultivated in vivo or derived from culture in vitro.
Par culture in vivo on entend toute culture de type classique c'est à dire en sol à l'air libre ou en serre, ou encore hors sol.The term “in vivo culture” means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
Par culture in vitro, on entend l'ensemble des techniques connues de l'homme du métier qui permet de manière artificielle l'obtention d'un végétal ou d'une partie d'un végétal. La pression de sélection imposée par les conditions physicochimiques lors de la croissance des cellules végétales in vitro permet d'obtenir un matériel végétal standardisé et disponible tout au long de l'année
contrairement aux plantes cultivées in vivo.The term “in vitro culture” means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant. The selection pressure imposed by the physicochemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material available throughout the year. unlike plants grown in vivo.
Préférentiellement selon l'invention on utilise un végétal issu de culture in vivo.Preferably, according to the invention, a plant originating from culture in vivo is used.
Toute méthode d'extraction connue de l'homme du métier peut être utilisée pour préparer l'extrait contenu dans la composition selon l'invention.Any extraction method known to those skilled in the art can be used to prepare the extract contained in the composition according to the invention.
On peut en particulier citer les extraits aqueux, alcooliques ou utilisant un solvant organique.Mention may in particular be made of aqueous extracts, alcoholic extracts or those using an organic solvent.
Par solvant aqueux on entend tout solvant constitué totalement ou pour part d'eau. On peut citer ainsi l'eau elle-même, les solvants hydroalcooliques en toute proportion ou encore les solvants constitués d'eau et d'un composé comme le propylène glycol en toute proportion.The term “aqueous solvent” means any solvent consisting wholly or partly of water. Mention may thus be made of water itself, hydroalcoholic solvents in any proportion or even solvents consisting of water and a compound such as propylene glycol in any proportion.
Parmi les solvants alcooliques on peut citer notamment l'éthanol.Mention may in particular be made, among alcoholic solvents, of ethanol.
On peut également utiliser un extrait préparé par la méthode décrite dans la demande de brevet français n° 95-02379 déposée par la demanderesse. Ainsi, dans une première étape on broie le matériel végétal dans une solution aqueuse à froid, dans une deuxième étape les particules en suspension sont éliminées de la solution aqueuse issue de la première étape, et dans une troisième étape on stérilise la solution aqueuse issue de la deuxième étape. Cette solution aqueuse correspond à l'extrait.One can also use an extract prepared by the method described in French patent application No. 95-02379 filed by the applicant. Thus, in a first step the plant material is ground in a cold aqueous solution, in a second step the particles in suspension are removed from the aqueous solution obtained from the first step, and in a third step the aqueous solution obtained from the second step. This aqueous solution corresponds to the extract.
D'autre part, la première étape peut avantageusement être remplacée par une opération de congélation simple des tissus végétaux (par exemple à -20°C), suivie d'une extraction aqueuse reprenant les deuxièmes et troisième étapes ci- dessus décrites.On the other hand, the first step can advantageously be replaced by a simple freezing operation of the plant tissues (for example at -20 ° C.), followed by an aqueous extraction repeating the second and third steps described above.
Quel que soit le mode de préparation utilisé selon l'invention des étapes subséquentes visant à favoriser la conservation et/ou la stabilisation peuvent être ajoutées sans pour cela modifier la nature même de l'extrait. Ainsi, par exemple l'extrait obtenu peut être lyophilisé par toutes méthodes classiques de lyophilisation. On obtient ainsi une poudre qui peut être utilisée directement ou bien mélanger dans un solvant approprié avant utilisation.Whatever the mode of preparation used according to the invention, subsequent steps aimed at promoting conservation and / or stabilization can be added without modifying the very nature of the extract. Thus, for example, the extract obtained can be lyophilized by any conventional lyophilization method. A powder is thus obtained which can be used directly or else mix in an appropriate solvent before use.
On peut également citer des extrait commerciaux comme celui commercialisé par la société Euromed sous la dénomination Leucocyanidines de raisins extra, ou encore celui commercialisé par la société Indena sous la dénomination
Leucoselecl®, ou enfin celui commercialisé par , la société Hansen sous la dénomination extrait de marc de raisin.Mention may also be made of commercial extracts such as that marketed by the company Euromed under the name Leucocyanidins from extra grapes, or else that marketed by the company Indena under the name Leucoselecl®, or finally that marketed by, the company Hansen under the name grape marc extract.
Préférentiellement selon l'invention, on utilise un extrait commercialisé par la société Euromed sous la dénomination Leucocyanidines de raisins extra.Preferably according to the invention, an extract sold by the company Euromed under the name Leucocyanidins from extra grapes is used.
Selon l'invention, la quantité d'extrait de végétal de l'espèce Vitis vinifera utilisée dans la composition est bien entendu fonction de l'effet recherché et peut donc varier dans une large mesure.According to the invention, the amount of plant extract of the species Vitis vinifera used in the composition is of course a function of the desired effect and can therefore vary to a large extent.
Pour donner un ordre de grandeur, selon l'invention, l'extrait peut être utilisé en une quantité représentant de 10"4% à 20% du poids total de la composition et préférentiellement en une quantité représentant de 5.10"3% à 10% du poids total de la composition.To give an order of magnitude, according to the invention, the extract can be used in an amount representing from 10 "4 % to 20% of the total weight of the composition and preferably in an amount representing from 5.10 " 3 % to 10% of the total weight of the composition.
Bien entendu, selon l'invention l'extrait d'au moins un végétal de l'espèce Vitis vinifera peut être associé à d'autres inhibiteurs de NO-synthases comme par exemple le lipochroman-6, ou d'autres extraits végétaux comme par exemple un extrait de Ginkgo biloba, un extrait d'Olea europaea ou encore un extrait de thé vert ou de cacao.Of course, according to the invention, the extract of at least one plant of the Vitis vinifera species can be combined with other NO-synthase inhibitors such as, for example, lipochroman-6, or other plant extracts such as example an extract of Ginkgo biloba, an extract of Olea europaea or an extract of green tea or cocoa.
L'invention a pour neuvième objet un procédé de traitement cosmétique en vue de traiter les désordres liés à la synthèse du NO, caractérisé par le fait que l'on utilise par application sur la peau, sur les cheveux, et/ou sur les muqueuses, une composition cosmétique comprenant au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera dans un milieu physiologiquement acceptable.The ninth subject of the invention is a cosmetic treatment process with a view to treating disorders linked to the synthesis of NO, characterized in that it is used by application on the skin, on the hair, and / or on the mucous membranes , a cosmetic composition comprising at least one extract of at least one plant of the Vitis vinifera species in a physiologically acceptable medium.
Le procédé de traitement cosmétique de l'invention vise à améliorer l'aspect de l'individu atteint par les désordres dus à la synthèse du NO.The cosmetic treatment method of the invention aims to improve the appearance of the individual affected by the disorders due to the synthesis of NO.
Le procédé de traitement cosmétique de l'invention peut être mis en œuvre notamment en appliquant les compositions cosmétiques telles que définies ci- dessus, selon la technique d'utilisation habituelle de ces compositions. Ainsi par exemple il est possible d'effectuer des applications de crèmes, de gels, de sérums, de lotions, de laits de démaquillage ou de compositions anti-solaires sur la peau ou sur les cheveux secs, des applications d'une lotion pour cheveux sur cheveux mouillés, de shampooings, ou encore des applications de dentifrice sur les gencives.
Quelque soit la forme de la composition selon l'invention dans laquelle l'extrait est utilisé, celle-ci peut être ingérée, injectée ou appliquée sur la peau (sur toute zone cutanée du corps), les cheveux, les ongles ou les muqueuses (buccale, jugale, gingivale, génitale, conjonctive). Selon le mode d'administration, la composition selon l'invention peut se présenter sous toutes les formes galéniques normalement utilisées.The cosmetic treatment process of the invention can be implemented in particular by applying the cosmetic compositions as defined above, according to the usual technique for using these compositions. Thus for example it is possible to carry out applications of creams, gels, serums, lotions, cleansing milks or anti-sun compositions on the skin or on dry hair, applications of a hair lotion on wet hair, shampoos, or even toothpaste applications on the gums. Whatever the form of the composition according to the invention in which the extract is used, it can be ingested, injected or applied to the skin (on any cutaneous zone of the body), the hair, the nails or the mucous membranes ( buccal, jugale, gingival, genital, conjunctiva). Depending on the mode of administration, the composition according to the invention can be in all the dosage forms normally used.
Pour une application topique sur la peau, la composition peut avoir la forme notamment de solution aqueuse ou huileuse ou de dispersion du type lotion ou sérum, d'émulsions de consistance liquide ou semi-liquide du type lait, obtenues par dispersion d'une phase grasse dans une phase aqueuse (H/E) ou inversement (E/H), ou de suspensions ou émulsions de consistance molle du type crème ou gel aqueux ou anhydres, ou encore de microcapsules ou microparticules, ou de dispersions vésiculaires de type ionique et/ou non ionique. Ces compositions sont préparées selon les méthodes usuelles.For topical application to the skin, the composition may take the form in particular of an aqueous or oily solution or of a dispersion of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a phase fatty in an aqueous phase (O / W) or vice versa (W / O), or of suspensions or emulsions of soft consistency of the aqueous or anhydrous cream or gel type, or of microcapsules or microparticles, or of vesicular dispersions of the ionic type and / or non-ionic. These compositions are prepared according to the usual methods.
Elles peuvent être également utilisées pour les cheveux sous forme de solutions aqueuses, alcooliques ou hydroalcooliques, ou sous forme de crèmes, de gels, d'émulsions, de mousses ou encore sous forme de compositions pour aérosol comprenant également un agent propulseur sous pression.They can also be used for the hair in the form of aqueous, alcoholic or hydroalcoholic solutions, or in the form of creams, gels, emulsions, foams or also in the form of aerosol compositions also comprising a propellant under pressure.
Pour l'injection, la composition peut se présenter sous forme de lotion aqueuse, huileuse ou sous forme de sérum. Pour les yeux, elle peut se présenter sous forme de gouttes et pour l'ingestion, elle peut se présenter sous forme de capsules, de granulés de sirops ou de comprimés.For injection, the composition may be in the form of an aqueous, oily lotion or in the form of a serum. For the eyes, it can be in the form of drops and for ingestion, it can be in the form of capsules, granules of syrups or tablets.
Les quantités des différents constituants des compositions selon l'invention sont celles classiquement utilisées dans les domaines considérés.The amounts of the various constituents of the compositions according to the invention are those conventionally used in the fields considered.
Ces compositions constituent notamment des crèmes de nettoyage, de protection, de traitement ou de soin pour le visage, pour les mains, pour les pieds, pour les grands plis anatomiques ou pour le corps, (par exemple crèmes de jour, crèmes de nuit, crèmes démaquillantes, crèmes de fond de teint, crèmes anti-solaires), des fonds de teint fluides, des laits de démaquillage, des laits corporels de protection ou de soin, des laits anti-solaires, des lotions, gels ou mousses pour le soin de la peau, comme des lotions de nettoyage, des lotions anti-solaires, des lotions de bronzage artificiel, des compositions pour le bain,
des compositions désodorisantes comprenant un agent bactéricide, des gels ou lotions après-rasage, des crèmes épilatoires, des compositions contre les piqûres d'insectes, des compositions anti-douleur, des compositions pour traiter certaines maladies de la peau comme l'eczéma, la rosasée, le psoriasis, les lichens, les prurits sévères.These compositions constitute in particular cleansing, protective, treatment or care creams for the face, for the hands, for the feet, for large anatomical folds or for the body (for example day creams, night creams, make-up remover creams, foundation creams, sunscreen creams), fluid foundations, make-up removal milks, body protection or care milks, anti-sun milks, lotions, gels or foams for care skin, such as cleansing lotions, sunscreen lotions, artificial tanning lotions, bath compositions, deodorant compositions comprising a bactericidal agent, aftershave gels or lotions, depilatory creams, compositions against insect bites, pain relieving compositions, compositions for treating certain skin diseases such as eczema, rosacea, psoriasis, lichens, severe pruritus.
Les compositions selon l'invention peuvent également consister en des préparations solides constituant des savons ou des pains de nettoyage.The compositions according to the invention may also consist of solid preparations constituting soaps or cleaning bars.
Les compositions peuvent aussi être conditionnées sous forme de composition pour aérosol comprenant également un agent propulseur sous pression.The compositions can also be packaged in the form of an aerosol composition also comprising a propellant under pressure.
La composition selon l'invention peut aussi être une composition pour soins capillaires, et notamment un shampooing, une lotion de mise en plis, une lotion traitante, une crème ou un gel coiffant, une composition de teintures (notamment teintures d'oxydation) éventuellement sous forme de shampooings colorants, des lotions restructurantes pour les cheveux, une composition de permanente (notamment une composition pour le premier temps d'une permanente), une lotion ou un gel antichute, un shampooing antiparasitaire, etc.The composition according to the invention may also be a composition for hair care, and in particular a shampoo, a styling lotion, a treating lotion, a styling cream or gel, a composition of dyes (in particular oxidation dyes) in the form of coloring shampoos, restructuring hair lotions, a perm composition (in particular a composition for the first time of a perm), a fall prevention lotion or gel, an antiparasitic shampoo, etc.
La composition peut aussi être à usage bucco-dentaire, par exemple une pâte dentifrice. Dans ce cas, la composition peut contenir des adjuvants et additifs usuels pour les compositions à usage buccal et notamment des agents tensioactifs, des agents épaississants, des agents humectants, des agents de polissage tels que la silice, divers ingrédients actifs comme les fluorures, en particulier le fluorure de sodium, et éventuellement des agents édulcorants comme le saccharinate de sodium.The composition can also be for oral use, for example a toothpaste. In this case, the composition may contain adjuvants and additives customary for compositions for oral use and in particular surfactants, thickening agents, humectants, polishing agents such as silica, various active ingredients such as fluorides, in particular particularly sodium fluoride, and optionally sweetening agents such as sodium saccharinate.
Lorsque la composition est une émulsion, la proportion de la phase grasse peut aller de 5 % à 80 % en poids, et de préférence de 5 % à 50 % en poids par rapport au poids total de la composition. Les huiles, les cires, les émulsionnants et les coémulsionnants utilisés dans la composition sous forme d'émulsion sont choisis parmi ceux classiquement utilisés dans le domaine cosmétique. L'émulsionnant et le coémulsionnant sont présents, dans la composition, en une proportion allant de 0,3 % à 30 % en poids, et de préférence de 0,5 à 20 % en poids par rapport au poids total de la composition. L'émulsion peut, en outre, contenir des vésicules lipidiques.When the composition is an emulsion, the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition. The oils, waxes, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic field. The emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition. The emulsion may, in addition, contain lipid vesicles.
Lorsque la composition est une solution ou un gel huileux, la phase grasse peut
représenter plus de 90 % du poids total de la composition.When the composition is an oily solution or gel, the fatty phase may represent more than 90% of the total weight of the composition.
De façon connue, la composition cosmétique peut contenir également des adjuvants habituels dans le domaine cosmétique, tels que les gélifiants hydrophiles ou lipophiles, les additifs hydrophiles ou lipophiles, les conservateurs, les antioxydants, les solvants, les parfums, les charges, les filtres, les absorbeurs d'odeur et les matières colorantes. Les quantités de ces différents adjuvants sont celles classiquement utilisées dans le domaine cosmétique, et par exemple de 0,01 % à 10 % du poids total de la composition. Ces adjuvants, selon leur nature, peuvent être introduits dans la phase grasse, dans la phase aqueuse et/ou dans les sphérules lipidiques.In a known manner, the cosmetic composition may also contain adjuvants customary in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and coloring matters. The amounts of these various adjuvants are those conventionally used in the cosmetic field, and for example from 0.01% to 10% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid spherules.
Comme huiles ou cires utilisables dans l'invention, on peut citer les huiles minérales (huile de vaseline), les huiles végétales (fraction liquide du beurre de karité, huile de tournesol), les huiles animales (perhydrosqualène), les huiles de synthèse (huile de Purcellin), les huiles ou cires siliconees (cyclomethicone) et les huiles fluorées (perfluoropolyéthers), les cires d'abeille, de camauba ou paraffine. On peut ajouter à ces huiles des alcools gras et des acides gras (acide stéarique).As oils or waxes which can be used in the invention, mention may be made of mineral oils (petroleum jelly oil), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils ( Purcellin oil), silicone oils or waxes (cyclomethicone) and fluorinated oils (perfluoropolyethers), beeswax, camauba or paraffin. Fatty alcohols and fatty acids (stearic acid) can be added to these oils.
Comme émulsionnants utilisables dans l'invention, on peut citer par exemple le stéarate de glycérol, le polysorbate 60 et le mélange de PEG-6/PEG-32/Glycol Stéarate vendu sous la dénomination de TefoseR 63 par la société Gattefosse.As emulsifiers which can be used in the invention, there may be mentioned for example glycerol stearate, polysorbate 60 and the mixture of PEG-6 / PEG-32 / Glycol Stearate sold under the name Tefose R 63 by the company Gattefosse.
Comme solvants utilisables dans l'invention, on peut citer les alcools inférieurs, notamment l'éthanol et l'isopropanol, le propylène glycol.As solvents which can be used in the invention, mention may be made of lower alcohols, in particular ethanol and isopropanol, propylene glycol.
Comme gélifiants hydrophiles utilisables dans l'invention, on peut citer les polymères carboxyvinyliques (carbomer), les copolymères acryliques tels que les copolymères d'acrylates/alkylacrylates, les polyacrylamides, les polysaccharides tels que l'hydroxypropylcellulose, les gommes naturelles et les argiles, et, comme gélifiants lipophiles, on peut citer les argiles modifiées comme les bentones, les sels métalliques d'acides gras comme les stéarates d'aluminium et la silice hydrophobe, éthylcellulose, polyéthylène.As hydrophilic gelling agents which can be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, ethylcellulose, polyethylene.
La composition peut contenir d'autres actifs hydrophiles comme les protéines ou les hydrolysats de protéine, les acides aminés, les polyols, l'urée, l'allantoïne, les sucres et les dérivés de sucre, les vitamines hydrosolubles, les extraits végétaux
et les hydroxyacides.The composition may contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, plant extracts and hydroxy acids.
Comme actifs lipophiles, on peut utiliser le rétinol (vitamine A) et ses dérivés, le tocophérol (vitamine E) et ses dérivés, les acides gras essentiels, les céramides, les huiles essentielles, l'acide salicylique et ses dérivés.As lipophilic active agents, retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils, salicylic acid and its derivatives can be used.
Selon l'invention la composition peut associer au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera à d'autres agents actifs destinés notamment à la prévention et/ou au traitement des affections cutanées. Parmi ces agents actifs, on peut citer à titre d'exemple :According to the invention, the composition can combine at least one extract of at least one plant of the Vitis vinifera species with other active agents intended in particular for the prevention and / or treatment of skin conditions. Among these active agents, there may be mentioned by way of example:
- les agents modulant la différenciation et/ou la prolifération et/ou la pigmentation cutanée tels que l'acide rétinoïque et ses isomères, le rétinol et ses esters, la vitamine D et ses dérivés, l'acide kojique ou l'hydroquinone ;- agents modulating differentiation and / or proliferation and / or skin pigmentation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, kojic acid or hydroquinone;
- les antibactériens tels que le phosphate de clindamycine, l'érythromycine ou les antibiotiques de la classe des tétracyclines ;- antibacterials such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline class;
- les antiparasitaires, en particulier le métronidazole, le crotamiton ou les pyréthrinoïdes ;- antiparasitics, in particular metronidazole, crotamiton or pyrethroids;
- les antifongiques, en particulier les composés appartenant à la classe des imidazoles tels que Péconazole, le kétoconazole ou le miconazole ou leurs sels, les composés polyènes, tels que l'amphotéricine B, les composés de la famille des allylamines, tels que la terbinafine, ou encore l'octopirox ;- antifungals, in particular compounds belonging to the class of imidazoles such as Peconazole, ketoconazole or miconazole or their salts, polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine , or octopirox;
- les agents anti-inflammatoires non-stéroïdiens tels que l'ibuprofène et ses sels, le diclofenac et ses sels, l'acide acétylsalicylique, l'acetaminophène ou l'acide glycyrrhétinique ;- non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid, acetaminophen or glycyrrhetinic acid;
- les agents anesthésiques tels que le chlorhydrate de lidocaïne et ses dérivés ;- anesthetic agents such as lidocaine hydrochloride and its derivatives;
- les agents antiprurigineux comme la thénaldine, la triméprazine ou la cyproheptadine ;- antipruritic agents such as thenaldine, trimeprazine or cyproheptadine;
- les agents kératolytiques tels que les acides alpha- et bêta- hydroxycarboxyliques ou bêta-cétocarboxyliques, leurs sels, amides ou esters et plus particulièrement les hydroxyacides tels que l'acide glycolique, l'acide lactique, l'acide salicylique, l'acide citrique et de manière générale les acides de fruits, et l'acide n-octanoyl-5-salicylique ;- keratolytic agents such as alpha- and beta-hydroxycarboxylic or beta-ketocarboxylic acids, their salts, amides or esters and more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, acid citric and generally fruit acids, and n-octanoyl-5-salicylic acid;
- les agents anti-radicaux libres, tels que l'alpha-tocophérol ou ses esters, les superoxyde dismutases, certains chelatants de métaux ou l'acide ascorbique et ses esters ;- anti-free radical agents, such as alpha-tocopherol or its esters, superoxide dismutases, certain metal chelating agents or ascorbic acid and its esters;
- les anti-séborrhéiques tels que la progestérone ;- anti-seborrheic drugs such as progesterone;
- les antipelliculaires comme l'octopirox ou la pyrithione de zinc ;- anti-dandruff agents such as octopirox or zinc pyrithione;
- les antiacnéiques comme l'acide rétinoïque ou le peroxyde de benzoyle ;
- les extraits végétaux ou d'origine microbienne,- anti-acne drugs such as retinoic acid or benzoyl peroxide; - plant or microbial extracts,
- les peptides et leur dérivés comme par exemple le tripeptide Lys-Pro-Val.- peptides and their derivatives such as for example the tripeptide Lys-Pro-Val.
Les exemples et compositions suivants illustrent l'invention sans la limiter aucunement. Dans les compositions les proportions indiquées sont des pourcentages en poids.The following examples and compositions illustrate the invention without limiting it in any way. In the compositions the proportions indicated are percentages by weight.
Exemple 1 : Activité biologique d'extraits commerciaux de végétal de l'espèceExample 1 Biological Activity of Commercial Plant Extracts of the Species
Vitis vinifera :Vitis vinifera:
L'essai est réalisé avec trois extraits commerciaux à savoir :The test is carried out with three commercial extracts, namely:
1 : Extrait commercialisé par la société Euromed sous la dénomination Leucocyanidines de raisins extra,1: Extract sold by the company Euromed under the name Leucocyanidins from extra grapes,
2 : Extrait commercialisé par la société Indena sous la dénomination Leucoselect®,2: Extract sold by Indena under the name Leucoselect®,
3 : Extrait commercialisé par la société Hansen sous la dénomination extrait de marc de raisin.3: Extract sold by the company Hansen under the name extract of grape marc.
L'activité des extraits sur la NO-synthase inductible a été évalué dans le test décrit par Heck et col. (J.B.C., Vol. 267, N°30, 21277-21280, 25 octobre 1992). Ce test a pour objectif de montrer la diminution de la concentration en nitrate et nitrite, in fine, après stimulation de la NO-synthase 2.The activity of the extracts on inducible NO synthase was evaluated in the test described by Heck et al. (J.B.C., Vol. 267, N ° 30, 21277-21280, October 25, 1992). The objective of this test is to show the decrease in the concentration of nitrate and nitrite, in fine, after stimulation of NO-synthase 2.
A : contrôle positif (induction de l'enzyme) : mélanges d'interféron-γ (1 OOOU/ml) et d'Interleukine 1-β (100 U/ml) ; B : contrôle négatif (inhibition maximale) : NG-monométhyl-L-arginine (forme L) à 200 μM ; C : contrôle de spécificité de l'inhibition : NG-monométhyl-L-arginine (forme D) àA: positive control (induction of the enzyme): mixtures of interferon-γ (1 OOOU / ml) and Interleukin 1-β (100 U / ml); B: negative control (maximum inhibition): N G -monomethyl-L-arginine (form L) at 200 μM; C: inhibition specificity control: N G -monomethyl-L-arginine (form D) at
200 μM.200 μM.
Pour déterminer l'activité du produit à tester on mesure la quantité de produits de réaction stables du NO (nitrites et nitrates) à l'aide du kit "nitric colorimetric assay" vendu par la société Boehringer sous la référence 1756.28.To determine the activity of the product to be tested, the quantity of stable NO reaction products (nitrites and nitrates) is measured using the “nitric colorimetric assay” kit sold by the company Boehringer under the reference 1756.28.
Ch aque extrait a été testé aux concentrations de 0,001%, 0,005% et 0,01% (poids/volume).Each extract was tested at concentrations of 0.001%, 0.005% and 0.01% (weight / volume).
Les extraits présentent un effet inhibiteur de la NO-synthase inductible.The extracts have an inhibitory effect on inducible NO synthase.
Exemple 2 :Example 2:
Exemples de formulations illustrant l'invention. Ces compositions ont été obtenues par simple mélange des différents composants.Examples of formulations illustrating the invention. These compositions were obtained by simple mixing of the various components.
Composition 1 : LotionComposition 1: Lotion
Extrait 1 2,00 %Extract 1 2.00%
Antioxydant 0,05 %Antioxidant 0.05%
Isopropanol 40,00 %Isopropanol 40.00%
Conservateur 0,30 %Preservative 0.30%
Eau qsp 100 %Water qs 100%
Composition 2 : Gel pour le soinComposition 2: Gel for care
Extrait 2 • 3,00 %Extract 2 • 3.00%
Hydroxypropylcellulose* 1 ,00 %Hydroxypropylcellulose * 1, 00%
Antioxydant 0,05 %Antioxidant 0.05%
Isopropanol 40,00 o //oIsopropanol 40.00 o // o
Conservateur 0,30 %Preservative 0.30%
Eau qsp 100 %Water qs 100%
Composition 3 : Crème de soin (émulsion huile dans eau)Composition 3: Care cream (oil in water emulsion)
Extrait 3 5,00 %Extract 3 5.00%
Stéarate de glycérol 2,00 %Glycerol stearate 2.00%
Polysorbate 60** 1 ,00 %Polysorbate 60 ** 1, 00%
Acide stéarique 1 ,40 %
Triéthanolamine 0,70 %Stearic acid 1.40% Triethanolamine 0.70%
Carbomer 0,40 %Carbomer 0.40%
Fraction liquide du beurre de karité 12,00 %Liquid fraction of shea butter 12.00%
Perhydrosqualène 12,00 %Perhydrosqualene 12.00%
Antioxydant 0,05 %Antioxidant 0.05%
Parfum 0,50 %Perfume 0.50%
Conservateur 0,30 %Preservative 0.30%
Eau qsp 100 %Water qs 100%
Composition 4 : ShampooingComposition 4: Shampoo
Extrait 3 0,50 %Extract 3 0.50%
Hydroxypropylcellulose* 1,00 %Hydroxypropylcellulose * 1.00%
Parfum 0,50 %Perfume 0.50%
Conservateur 0,30 %Preservative 0.30%
Eau qsp 100 %Water qs 100%
Composition 5 : Crème de soin (émulsion huile/eau)Composition 5: Care cream (oil / water emulsion)
Extrait 1 5,00 %Extract 1 5.00%
Stéarate de glycérol 2,00 %Glycerol stearate 2.00%
Polysorbate 60** 1 ,00 %Polysorbate 60 ** 1, 00%
Acide stéarique 1 ,40 %Stearic acid 1.40%
Acide n-octanoyl-5-salicylique 0,50 %N-octanoyl-5-salicylic acid 0.50%
Triéthanolamine 0,70 %Triethanolamine 0.70%
Carbomer 0,40 %Carbomer 0.40%
Fraction liquide du beurre de karité 12,00 %Liquid fraction of shea butter 12.00%
Perhydrosqualène 12,00 %Perhydrosqualene 12.00%
Antioxydant 0,05 %Antioxidant 0.05%
Parfum 0,50 %Perfume 0.50%
Conservateur 0,30 %Preservative 0.30%
Eau qsp 100 %Water qs 100%
Composition 6 : Gel anti-douleurComposition 6: Pain relieving gel
Extrait 2 5,00 %Extract 2 5.00%
Hydroxypropylcellulose* 1 ,00 %Hydroxypropylcellulose * 1, 00%
Antioxydant 0,05 %Antioxidant 0.05%
Chlorhydrate de lidocaïne 2,00 %Lidocaine hydrochloride 2.00%
Isopropanol 40,00 %Isopropanol 40.00%
Conservateur 0,30 %
Eau qsp 100 %Preservative 0.30% Water qs 100%
Composition 7 : Crème de soin de l'érythème solaire (émulsion huile-dans-eau)Composition 7: Sun erythema care cream (oil-in-water emulsion)
Extrait 1 5,00 %Extract 1 5.00%
Stéarate de glycérol 2,00 %Glycerol stearate 2.00%
Polysorbate 60** 1 ,00 %Polysorbate 60 ** 1, 00%
Acide stéarique 1 ,40 %Stearic acid 1.40%
Acide glycyrrhétinique 2,00 %Glycyrrhetinic acid 2.00%
Triéthanolamine 0,70 %Triethanolamine 0.70%
Carbomer 0,40 %Carbomer 0.40%
Fraction liquide du beurre de karité 12,00 %Liquid fraction of shea butter 12.00%
Huile de tournesol 10,00 %Sunflower oil 10.00%
Antioxydant 0,05 %Antioxidant 0.05%
Parfum 0,50 %Perfume 0.50%
Conservateur 0,30 %Preservative 0.30%
Eau qsp 100 %Water qs 100%
Composition 8 : Gel pour le traitement de l'acnéComposition 8: Gel for the treatment of acne
Extrait 3 5,00 %Extract 3 5.00%
Acide tout trans rétinoïque 0,05 %0.05% all trans retinoic acid
Hydroxypropylcellulose* 1 ,00 %Hydroxypropylcellulose * 1, 00%
Antioxydant 0,05 %Antioxidant 0.05%
Isopropanol 40,00 % Conservateur 0,30 %Isopropanol 40.00% Preservative 0.30%
Eau qsp 100 ' %Water qs 100 ' %
Composition 9 : Lotion pour éliminer les cicatrices dues à l'acnéComposition 9: Lotion for eliminating scars due to acne
Extrait 2 3,00 %Extract 2 3.00%
Acide glycolique 50,00 %Glycolic acid 50.00%
Hydroxypropylcellulose* 0,05 %Hydroxypropylcellulose * 0.05%
Conservateur 0,30 %Preservative 0.30%
NaOH qsp pH = 2,8NaOH qs pH = 2.8
Ethanol qsp 100 %Ethanol qs 100%
* : Klucel H® vendu par la société Hercules ** : Tween 60® vendu par la société ICI
* : Klucel H® sold by the company Hercules ** : Tween 60® sold by the company HERE
Claims
1. Utilisation d'une quantité efficace d'au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera, dans un milieu physiologiquement acceptable, dans une composition ou pour la préparation d'une composition, l'extrait ou la composition étant destinés à inhiber la NO-synthase.1. Use of an effective amount of at least one extract of at least one plant of the species Vitis vinifera, in a physiologically acceptable medium, in a composition or for the preparation of a composition, the extract or the composition being intended to inhibit NO synthase.
2. Utilisation selon la revendication précédente, caractérisée par le fait que l'extrait ou la composition sont destinés à ralentir voire inhiber la différenciation et/ou la prolifération cellulaire.2. Use according to the preceding claim, characterized in that the extract or the composition are intended to slow down or even inhibit cell differentiation and / or proliferation.
3. Utilisation selon la revendication précédente, caractérisée par le fait que l'extrait ou la composition sont destinés à ralentir voire inhiber la croissance de l'épiderme et ou à traiter les désordres hyperprolifératifs.3. Use according to the preceding claim, characterized in that the extract or the composition are intended to slow down or even inhibit the growth of the epidermis and or to treat hyperproliferative disorders.
4. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à inhiber la dégradation et/ou la destruction des cellules.4. Use according to claim 1, characterized in that the extract or the composition are intended to inhibit the degradation and / or destruction of cells.
5. Utilisation selon la revendication 1 ,- caractérisée par le fait que l'extrait ou la composition sont destinés à inhiber les processus apoptotiques cellulaires.5. Use according to claim 1, - characterized in that the extract or the composition are intended to inhibit cellular apoptotic processes.
6. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à traiter le vieillissement intrinsèque et/ou extrinsèque.6. Use according to claim 1, characterized in that the extract or the composition are intended to treat intrinsic and / or extrinsic aging.
7. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont . destinés à inhiber voire supprimer les processus immunologiques et/ou inflammatoires.7. Use according to claim 1, characterized in that the extract or the composition are. intended to inhibit or even suppress immunological and / or inflammatory processes.
8. Utilisation selon la revendication 7, caractérisée par le fait que l'extrait ou la composition sont destinés à traiter les réactions d'hypersensibilité de contact et/ou les manifestations allergiques et/ou la réponse immunitaire.8. Use according to claim 7, characterized in that the extract or the composition are intended for treating hypersensitivity reactions of contact and / or allergic manifestations and / or the immune response.
9. Utilisation selon la revendication 7, caractérisée par le fait que l'extrait ou la composition sont destinés à diminuer voir inhiber l'inflammation cutanée.9. Use according to claim 7, characterized in that the extract or the composition are intended to reduce or even inhibit skin inflammation.
10. Utilisation selon la revendication 9, caractérisée par le fait que l'extrait ou la composition sont destinés à traiter les processus inflammatoires neurogéniques cutanés.10. Use according to claim 9, characterized in that the extract or the composition are intended for treating neurogenic inflammatory processes skin.
11. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à traiter les peaux dites sensibles11. Use according to claim 1, characterized in that the extract or the composition are intended for treating so-called sensitive skin
12. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à traiter les érythèmes, particulièrement les érythèmes induits par les rayonnements ultra-violets.12. Use according to claim 1, characterized in that the extract or the composition are intended for treating erythemas, particularly erythemas induced by ultraviolet radiation.
13. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à traiter les éruptions erythemateuses localisées ou diffuses de la peau.13. Use according to claim 1, characterized in that the extract or the composition are intended for treating localized or diffuse erythematous eruptions of the skin.
14. Utilisation selon, la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à traiter la rosacée.14. Use according to claim 1, characterized in that the extract or the composition are intended for treating rosacea.
15. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à inhiber la mélanogenèse induite par les rayonnements ultraviolets de type A et/ou B et/ou à traiter les désordres de type hypermélanose.15. Use according to claim 1, characterized in that the extract or the composition are intended to inhibit melanogenesis induced by type A and / or B ultraviolet radiation and / or to treat disorders of hypermelanosis type.
16. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à contrôler la sudation.16. Use according to claim 1, characterized in that the extract or the composition are intended to control sweating.
17. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à stimuler la lipolyse.17. Use according to claim 1, characterized in that the extract or the composition are intended to stimulate lipolysis.
18. Utilisation selon la revendication 1 , caractérisée par le fait que l'extrait ou la composition sont destinés à inhiber la chute des cheveux.18. Use according to claim 1, characterized in that the extract or the composition are intended to inhibit hair loss.
19. Utilisation selon la revendication 1, caractérisée par le fait que l'extrait ou la composition ou la composition sont destinés à renforcer la fonction barrière de la peau.19. Use according to claim 1, characterized in that the extract or the composition or the composition are intended to reinforce the barrier function of the skin.
20. Utilisation selon la revendication 1, caractérisée par le fait que l'extrait ou la composition sont destinés à stimuler l'hydratation de la peau.20. Use according to claim 1, characterized in that the extract or the composition are intended to stimulate the hydration of the skin.
21. Utilisation selon l'une quelconque des revendications précédentes, caractérisée par le fait que l'extrait est en une quantité représentant de 10"4% à 20% du poids total de la composition.21. Use according to any one of the preceding claims, characterized in that the extract is in an amount representing from 10 "4 % to 20% of the total weight of the composition.
22. Utilisation selon la revendication précédente, caractérisée par le fait que l'extrait est en une quantité représentant de 5.10"3% à 10% du poids total de la composition.22. Use according to the preceding claim, characterized in that the extract is in an amount representing from 5.10 "3 % to 10% of the total weight of the composition.
23. Utilisation selon l'une quelconque des revendications précédentes, caractérisée par le fait que l'extrait est obtenu à partir de matériel végétal issu de plante entière ou de feuilles, de tiges, de fleurs, de pétales, de graines, de racines ou encore de cellules dédifférenciées.23. Use according to any one of the preceding claims, characterized in that the extract is obtained from plant material obtained from whole plant or from leaves, stems, flowers, petals, seeds, roots or still dedifferentiated cells.
24. Utilisation selon la revendication précédente, caractérisée par le fait que l'extrait est obtenu à partir de feuilles.24. Use according to the preceding claim, characterized in that the extract is obtained from leaves.
25. Utilisation selon l'une quelconque des revendications précédentes, caractérisée par le fait que l'extrait est obtenu à partir de matériel végétal issu d'au moins un végétal cultivé in vivo.25. Use according to any one of the preceding claims, characterized in that the extract is obtained from plant material obtained from at least one plant cultivated in vivo.
26. Procédé de traitement cosmétique en vue de traiter les désordres liés à la synthèse du NO, caractérisé par le fait que l'on utilise par application sur la peau, sur les cheveux, et/ou sur les muqueuses, une composition cosmétique comprenant au moins un extrait d'au moins un végétal de l'espèce Vitis vinifera dans un milieu physiologiquement acceptable. 26. Cosmetic treatment process with a view to treating disorders linked to the synthesis of NO, characterized in that use is made, by application to the skin, to the hair, and / or to the mucous membranes, of a cosmetic composition comprising at least at least one extract of at least one plant of the Vitis vinifera species in a physiologically acceptable medium.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0005521A FR2808190B1 (en) | 2000-04-28 | 2000-04-28 | PLANT EXTRACT OF THE SPECIES VITIS VINIFERA AS NO-SYNTHASE INHIBITOR AND USES |
FR0005521 | 2000-04-28 | ||
PCT/FR2001/001316 WO2001082887A1 (en) | 2000-04-28 | 2001-04-27 | Plant extract of the species vitis vinifera as no-synthase inhibitor and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1278508A1 true EP1278508A1 (en) | 2003-01-29 |
Family
ID=8849753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01929749A Ceased EP1278508A1 (en) | 2000-04-28 | 2001-04-27 | Plant extract of the species i vitis vinifera /i as no-synthase inhibitor and uses |
Country Status (6)
Country | Link |
---|---|
US (2) | US20030165589A1 (en) |
EP (1) | EP1278508A1 (en) |
JP (1) | JP2003532644A (en) |
CA (1) | CA2407311A1 (en) |
FR (1) | FR2808190B1 (en) |
WO (1) | WO2001082887A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1485064B1 (en) | 2002-03-20 | 2014-05-07 | Rachid Ennamany | Cosmetic composition comprising phytoalexines and method for production of phytoalexins |
FR2837385B1 (en) * | 2002-03-20 | 2004-05-28 | Rachid Ennamany | PROCESS FOR OBTAINING PHYTOALEXINS |
US20040258778A1 (en) * | 2003-03-31 | 2004-12-23 | Farmar Jill B. | Lactation cessation and breast engorgement compositions and method of use |
US7758902B2 (en) * | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
US7758903B2 (en) | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
CN1882354B (en) * | 2003-09-12 | 2012-07-04 | 捷通国际有限公司 | Cytokine modulators and related methods of use |
US7198807B2 (en) * | 2003-12-01 | 2007-04-03 | Triarco Industries, Inc. | Inhibition of P. acnes using botanical extracts |
FR2864446B1 (en) * | 2003-12-29 | 2006-03-03 | Secma Biotechnologies Marines | USE IN A COSMETIC OR PHARMACEUTICAL COMPOSITION OF AT LEAST ONE LYIPHILISATE OF DIFFERENTIATED VEGETABLE CELLS FOR DEPIGMENTING AND / OR LIGHTENING, PROTECTING AND REGENERATING EPIDERMA |
WO2005067691A2 (en) * | 2004-01-07 | 2005-07-28 | E-L Management Corporation | Cosmetic composition containing a protein and an enzyme inhibitor |
CN101588788B (en) * | 2007-01-08 | 2012-11-21 | 高丽雅娜化妆品股份有限公司 | Cosmetic composition for protecting skin against uv light and wrinkle improvement containing the extract of magnolia sieboldii flower extracts |
US20100173028A1 (en) * | 2007-09-04 | 2010-07-08 | Jun-Ki Min | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same |
KR101069907B1 (en) * | 2008-09-04 | 2011-10-05 | 재단법인 제주테크노파크 | A composition for skin whitening comprising extract, fraction or compound from Lindera erythrocarpa |
FR2938766B1 (en) * | 2008-11-26 | 2010-12-31 | Isp Investments Inc | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING VINE LEAF HYDROLYSAT (VITIS VINIFERA L.) AS ACONITASE ACTIVATOR ACTIVE INGREDIENT AND MITOCHONDRIA PROTECTOR |
FR2938769B1 (en) * | 2008-11-26 | 2010-12-31 | Isp Investments Inc | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING VINE LEAF HYDROLYSAT (VITIS VINIFERAL.) AS CYTOCHROME C ACTIVE ACTIVATOR |
FR2938765B1 (en) * | 2008-11-26 | 2010-12-31 | Isp Investments Inc | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING A VINE LEAF HYDROLYZATE (VITIS VINIFERA L.) AS ACTIVE INGREDIENT OF SIRT PROTEINS |
WO2013149323A1 (en) * | 2012-04-02 | 2013-10-10 | Ntegrity | Natural products for skin care |
JP2021518848A (en) * | 2018-04-04 | 2021-08-05 | 劉▲ユエ▼劭Liu, Yue−Shao | Chinese herbal composition for increasing hair volume, its manufacturing method, and its use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001078674A1 (en) * | 2000-04-18 | 2001-10-25 | Ceteris Holding B.V. -Amsterdam (Olanda)- Succursale Di Lugano | A composition based on natural extracts useful in the prevention and treatment of cutaneous wrinkles |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2555443B1 (en) * | 1983-09-08 | 1987-09-11 | Spinoglio Mario | ACID SHAVING CREAM WITH XANTHANE GUM |
IT1201151B (en) * | 1987-01-14 | 1989-01-27 | Indena Spa | PHOSPHOLIPID COMPLEXES WITH EXTRACTS FROM VITIS VINIFERA, PROCEDURE FOR THEIR PREPARATION AND COMPOSITIONS THAT CONTAIN THEM |
FR2643073B1 (en) * | 1989-02-15 | 1991-08-16 | Expansion Rech Phytochimie | PROCESS FOR THE PREPARATION OF PURIFIED FLAVAN-3-OL POLYPHENOLIC EXTRACTS AND EXTRACTS OBTAINED |
JPH06336423A (en) * | 1993-05-28 | 1994-12-06 | Kose Corp | External agent for skin |
JP3770922B2 (en) * | 1993-05-28 | 2006-04-26 | 株式会社コーセー | Topical skin preparation |
JPH06336421A (en) * | 1993-05-28 | 1994-12-06 | Kose Corp | External agent for skin |
JP3805798B2 (en) * | 1993-05-28 | 2006-08-09 | 株式会社コーセー | Cosmetics |
JPH06336422A (en) * | 1993-05-28 | 1994-12-06 | Kose Corp | External agent for skin |
JP3502415B2 (en) * | 1993-05-28 | 2004-03-02 | 株式会社コーセー | Maillard reaction inhibitor |
JP3432596B2 (en) * | 1993-06-22 | 2003-08-04 | 協和醗酵工業株式会社 | Hair restorer |
US5529769A (en) * | 1994-12-20 | 1996-06-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions containing betulinic acid |
FR2740339B1 (en) * | 1995-10-26 | 1997-12-05 | Oreal | USE OF AT LEAST ONE NO-SYNTHASE INHIBITOR IN THE TREATMENT OF SENSITIVE SKIN |
DE19711565A1 (en) * | 1997-02-21 | 1998-08-27 | Beiersdorf Ag | Preparations for the treatment of rosacea |
US5988838A (en) * | 1997-05-30 | 1999-11-23 | Rudenberg; Murray | Remotely activated high-candle power illumination |
JPH1171294A (en) * | 1997-08-29 | 1999-03-16 | Pias Arise Kk | Collagenase inhibitor |
JPH11240842A (en) * | 1998-02-24 | 1999-09-07 | Shiseido Co Ltd | Protease inhibitor |
FR2775686B1 (en) * | 1998-03-09 | 2006-07-28 | Pascal Commenil | INDUSTRIAL AND COMMERCIAL EXPLOITATION OF CUTICULAR LIPIDS IN THE BAY OF GRAPE IN PHARMACOLOGY AND COSMETOLOGY |
DE69940256D1 (en) * | 1998-04-29 | 2009-02-26 | Avon Prod Inc | COMPOSITION FOR SKIN BALANCE |
JP2002519312A (en) * | 1998-06-30 | 2002-07-02 | エイボン プロダクツ インコーポレーテッド | Skin whitening composition |
JP2000080023A (en) * | 1998-06-30 | 2000-03-21 | Kanebo Ltd | Beautifully whitening cosmetic and melanin-formation inhibitor |
JP2000026306A (en) * | 1998-07-14 | 2000-01-25 | Kikkoman Corp | Hyaluronidase inhibitor |
KR20000034037A (en) * | 1998-11-27 | 2000-06-15 | 박인배 | Grape seed extract as tyrosinase inhibitor |
JP4070065B2 (en) * | 1999-07-15 | 2008-04-02 | 株式会社資生堂 | Skin preparation for preventing and improving skin roughness |
JP2001072552A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Hair growth composition |
JP2001072563A (en) * | 1999-09-08 | 2001-03-21 | Kikkoman Corp | Agent for preventing body odor |
-
2000
- 2000-04-28 FR FR0005521A patent/FR2808190B1/en not_active Expired - Fee Related
-
2001
- 2001-04-27 JP JP2001579762A patent/JP2003532644A/en not_active Withdrawn
- 2001-04-27 WO PCT/FR2001/001316 patent/WO2001082887A1/en not_active Application Discontinuation
- 2001-04-27 CA CA002407311A patent/CA2407311A1/en not_active Abandoned
- 2001-04-27 US US10/258,814 patent/US20030165589A1/en not_active Abandoned
- 2001-04-27 EP EP01929749A patent/EP1278508A1/en not_active Ceased
-
2005
- 2005-08-26 US US11/211,475 patent/US20050281900A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001078674A1 (en) * | 2000-04-18 | 2001-10-25 | Ceteris Holding B.V. -Amsterdam (Olanda)- Succursale Di Lugano | A composition based on natural extracts useful in the prevention and treatment of cutaneous wrinkles |
Non-Patent Citations (1)
Title |
---|
See also references of WO0182887A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001082887A1 (en) | 2001-11-08 |
FR2808190B1 (en) | 2002-06-21 |
US20050281900A1 (en) | 2005-12-22 |
JP2003532644A (en) | 2003-11-05 |
FR2808190A1 (en) | 2001-11-02 |
CA2407311A1 (en) | 2001-11-08 |
US20030165589A1 (en) | 2003-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0892642B1 (en) | Use in a composition of an extract of at least one labiate of the genus rosmarinarus, cultured in vitro | |
EP0906752B1 (en) | Use of a plant extract of the Rosaceae family | |
CA2222303C (en) | Use of at least one no synthase inhibitor for treating sensitive skin | |
EP1278532B1 (en) | Plant extract of the olea europaea species as no-synthase inhibitor and uses | |
EP0909556B1 (en) | Rosaceae extract as bradykinin antagonist | |
EP1278508A1 (en) | Plant extract of the species i vitis vinifera /i as no-synthase inhibitor and uses | |
WO2002102345A2 (en) | Deferoxamine as an no synthase inhibitor and uses thereof | |
EP1278509A1 (en) | Lipochroman-6 as no-synthase inhibitor and uses | |
FR2811567A1 (en) | COMPOSITION, ESPECIALLY COSMETIC, COMPRISING DHEA AND / OR A PRECURSOR OR DERIVATIVE THEREOF, IN ASSOCIATION WITH AT LEAST ONE NO-SYNTHASE INHIBITOR | |
EP1331924A2 (en) | Use of carotenoids for treating ageing symptoms | |
FR2722100A1 (en) | PERVENCHE SEED EXTRACT AND COMPOSITION CONTAINING SAME | |
CA2322149A1 (en) | Use of a compound inhibiting the activity of a sodium channel and a calcium channel in a composition for topical use | |
EP1401393A2 (en) | No-synthase inhibitor and use thereof | |
FR2821549A1 (en) | Use of a carotenoid to increase dermal collagen and lessen or prevent signs of cutaneous aging | |
WO2001082929A2 (en) | Epichatechin as no-synthase inhibitor and uses | |
WO2002102343A1 (en) | Ascorbyl 2-hexadecanoate as a no-synthase inhibitor | |
FR2815862A1 (en) | COMPOSITION COMPRISING THE ASSOCIATION OF AT LEAST ONE EXTRACT OF AT LEAST ONE PLANT OF THE GENUS CAMELLIA AND AT LEAST ONE CAROTENOID | |
FR2746646A1 (en) | Use of extracts of non-photosynthetic filamentous bacteria as substance P antagonists | |
WO2002102342A1 (en) | No-synthase inhibitor and uses thereof | |
FR2738486A1 (en) | Cell extracts from plant of Iridaceae family | |
FR2785536A1 (en) | USE OF AN EXTRACT OF AT LEAST ONE VEGETABLE OF THE GENUS OCIMUM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20021128 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
17Q | First examination report despatched |
Effective date: 20040309 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20051118 |